ストックスクリーナーアプリを入手
0.9351
1.57%
-0.0149
アフターアワーズ：
.97
0.0349
+3.73%
前日終値:
$0.95
開ける：
$0.95
24時間の取引高:
675.07K
Relative Volume:
1.14
時価総額：
$43.97M
収益：
-
当期純損益:
$-40.56M
株価収益率:
-0.7992
EPS:
-1.17
ネットキャッシュフロー:
$-35.28M
1週間 パフォーマンス:
+1.69%
1か月 パフォーマンス:
-7.42%
6か月 パフォーマンス:
-33.21%
1年 パフォーマンス:
-70.69%
1日の値動き範囲:
$0.90
$0.95
1週間の範囲:
$0.90
$1.16
52週間の値動き範囲:
$0.8505
$3.405
Pds Biotechnology Corporation Stock (PDSB) Company Profile
名前
Pds Biotechnology Corporation
セクター
電話
800-208-3343
住所
303A COLLEGE ROAD EAST, PRINCETON
PDSB を他の銘柄と比較する
| 株式 | 価格 | 時価総額 | 収益 | 当期純利益 | 現金流量 | EPS |
|---|---|---|---|---|---|---|
PDSB
Pds Biotechnology Corporation
|
0.9351 | 44.67M | 0 | -40.56M | -35.28M | -1.17 |
|
VRTX
Vertex Pharmaceuticals Inc
|
425.57 | 107.66B | 11.39B | 3.64B | 3.50B | 13.99 |
|
REGN
Regeneron Pharmaceuticals Inc
|
651.80 | 68.74B | 14.25B | 4.58B | 3.88B | 41.77 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
456.04 | 58.93B | 3.21B | 43.57M | 221.36M | 0.2405 |
|
ARGX
Argen X Se Adr
|
818.50 | 50.51B | 3.06B | 1.28B | 447.35M | 19.67 |
|
INSM
Insmed Inc
|
189.60 | 41.29B | 447.02M | -1.18B | -868.57M | -6.1812 |
Pds Biotechnology Corporation Stock (PDSB) Upgrades & Downgrades
| 日付 | アクション | アナリスト | 評価の変更 |
|---|---|---|---|
| 2022-11-01 | 開始されました | B. Riley Securities | Buy |
| 2021-06-28 | 開始されました | Cantor Fitzgerald | Overweight |
| 2020-11-10 | アップグレード | H.C. Wainwright | Neutral → Buy |
| 2020-05-27 | 開始されました | Alliance Global Partners | Buy |
| 2020-03-09 | 開始されました | Noble Capital Markets | Outperform |
| 2019-10-24 | 開始されました | Chardan Capital Markets | Buy |
すべてを表示
Pds Biotechnology Corporation (PDSB) 最新ニュース
Is PDS Biotechnology Corporation stock entering bullish territory2025 Trade Ideas & Verified Swing Trading Watchlist - newser.com
Earnings visualization tools for PDS Biotechnology CorporationTrend Reversal & Reliable Trade Execution Plans - newser.com
What machine learning models say about PDS Biotechnology CorporationCPI Data & Fast Moving Trade Plans - newser.com
Is PDS Biotechnology Corporation stock positioned for long term growthJuly 2025 Trends & Safe Capital Growth Tips - newser.com
PDS Biotechnology Stock Logs Best Session In 2 Months After FDA Fast-Track Push For Cancer Drug — Retail Bets On Early Approval - Stocktwits
Building trade automation scripts for PDS Biotechnology CorporationTrade Exit Report & Safe Capital Growth Tips - newser.com
Multi factor analysis applied to PDS Biotechnology CorporationMarket Sentiment Report & AI Based Trade Execution Alerts - newser.com
PDS Biotechnology Seeks Accelerated FDA Pathway for Cancer Therapy - AD HOC NEWS
What dividend safety score for PDS Biotechnology Corporation stockTrade Volume Summary & Fast Moving Market Watchlists - newser.com
Is PDS Biotechnology Corporation stock a good choice for value investorsJuly 2025 Price Swings & Expert Curated Trade Setups - newser.com
Will PDS Biotechnology Corporation stock reach all time highs in 2025 - newser.com
PDS Biotechnology Corporation’s volatility index tracking explainedRate Hike & Low Drawdown Investment Strategies - newser.com
New Clinical and Translational Data on PDS Biotechnology’s Novel Investigational Cancer Therapies PDS0101 and PDS01ADC to be Presented at the 2025 Society for Immunotherapy of Cancer (SITC) Annual Meeting - The Manila Times
PDS Biotechnology Corporation Announces New Clinical and Translational Data on Pds0101 and Pds01adc to Be Presented At the 2025 Society for Immunotherapy of Cancer Annual Meeting - MarketScreener
PDS Biotech to seek expedited approval pathway for PDS0101 in HPV16-positive head and neck cancer - MarketScreener
PDS Biotechnology Corporation Seeks Expedited Approval Pathway for PDS0101 in HPV16-Positive Head and Neck Cancer Following Promising VERSATILE-002 Trial Results - Quiver Quantitative
PDSB seeks FDA meeting to explore expedited path for PDS0101 - Stock Titan
39.3-month mOS seen with PDS0101 as PDS Biotech (NASDAQ: PDSB) seeks FDA expedited path - Stock Titan
Will PDS Biotechnology Corporation stock go up soon2025 Top Gainers & Technical Pattern Alert System - newser.com
Pds Biotechnology Corporation (PDSB) 財務データ
収益
当期純利益
現金流量
EPS
1.62%
0.21%
大文字化:
|
ボリューム (24 時間):